Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (14954)	12/26/2004 11:32:46 PM
From: Henry Niman	Respond to of 52153

>>trying to piece together something that sounds intelligent from PubMed<< Actually, I took my PhD at USC in 1978 and misread the affiliation of Nayak (I thought he might have switched to USC after I left) and recall you mentioning monoclonals at USC. In any event, if you made monoclonals against MHV, you should know that coronaviruses cause colds in humans (before SARS) and predicting SARS symptoms in the summer would have been much more of a guess than anything else. If fact, later SARS infections (jumping from lab isolates) generally were quite a bit milder than the versions that initially came out of the Metropole Hotel. Bottom line is that you STILL haven't addressed the nonsense that you posted about cold symptoms not being biologically relevant for a cold virus (regardless of how many post docs you did). I did take Mike Lai's RNA virus course in 1975 and don't recall any comments about coronaviruses not being able to cause cold symptoms (since they are probably responsible for 20-30% of human colds).

To: scaram(o)uche who wrote (14954)	12/27/2004 8:13:08 AM
From: Henry Niman	Read Replies (1) \| Respond to of 52153

>>But you're a fake, trying to piece together something that sounds intelligent from PubMed.<< Actually, its not that hard to verify my credentials. When I was taking my PhD at USC from 1974-78 I was working on feline RNA tumor viruses. First publication was in Nature (with John Stephenson who started Oncogene Sciences) and chief competitor was Ed Skolnik (who left NIH to head up research for MRK). I didn't work with flu until I went to Scripps, but even then it was just to make monoclonals against synthetic peptides. However, one of the flu monoclonals I made became one of the most popular monoclonals in the world. If you google 12CA5 (searches are free) you will get over 20,000 hits, most of which are to articles using 12CA5 google.com if you search 12CA5 monoclonal google.com you will get almost 15,000 hits and almost all will be on the 12CA5 monolconal If you search 12CA5 niman google.com you can get to my 1983 PNAS article descibing the various flu monoclonals I made or the 1984 Cell article describing the location of the epitope in the flu HA trimer. There are many more references (just search HA monoclonal and you will get almost 1/4 million hits) google.com because the monoclonal became so widely used that just about anyone would know which monoclonal you were talking about if you just said HA monolclonal since its the only HA monoclonal that was used in just about every biotech, pharma, or research center that did any molecular biology (the monoclonal was used in epitope tagging procedures worldwide). However, if you want to talk about something sounding fake, its a post saying that a human cold virus can't cause cold symptoms in humans.